论文部分内容阅读
Objective:To investigate the protective effect of IL-22 and IL-12 on cutaneous leishmaniasisin BALB/c mice.Methods:The protective effect of IL-22 and IL-I2 on cutaneous leishmanias in BALB/c mice was evaluated by measurement of IL-4.INF-γ.total IgG,IgG1 and IgG2 a after challenge with Leishamania major.Clinical evaluations were performed by measurement of lesion diameter,and survival rate of the mice.Results:In week 27 post infection,the mortality rates for control groups were 100%.While the survival rates for the IL-12.IL-12 + IL-22.and IL-22(5 ng/g) groups were 100%.The size of lesions decreased in the presence IL-22(5 ng/g) of mice weight,which was statistically significant in comparison with other groups(P<0.05).Mean of total IgG,IgG1 and IgG2 a for IL-22(5 ng/g) group was more than other groups.In IL-22 group(5 ng/g).INF—γ production was significantly higher than other groups and IL-4 was significantly lower than other groups.Conclusions:The results obtained indicate the effectiveness of IL-22 and its effect on IL-12 in protection of cutaneous leishmaniasis.
Objective: To investigate the protective effect of IL-22 and IL-12 on cutaneous leishmaniasis in BALB / c mice. Methods: The protective effect of IL-22 and IL-12 on cutaneous leishmanias in BALB / c mice was evaluated by measurement of IL -4.INF- [gamma]. Total IgG, IgGl and IgG2 a after challenge with Leishamania major. Clinical evaluations were performed by measurement of lesion diameter, and survival rate of the mice. Results: In week 27 post infection, the mortality rate for control groups were 100% .While the survival rates for the IL-12.IL-12 + IL-22 and IL-22 (5 ng / g) 5 ng / g) of mice weight, which was significantly significant in comparison with other groups (P <0.05). In IL-22 group (5 ng / g) .INF-γ production was significantly higher than other groups and IL-4 was significantly lower than other groups. Conclusions: The results obtained indicate the effec tiveness of IL-22 and its effect on IL-12 in protection of cutaneous leishmaniasis.